{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"Patients scored by the study chairs as no variation or minor variation were considered compliant, while patients scored as major variation or inevaluable were considered non-compliant. The number being reported is the number non-compliant. A compliance rate of 90% was targeted with 75% or lower being considered unacceptable. Fifty-seven patients were required with types I and II error rates both 0.10. If 10 or more patients out of 57 were non-compliant, the treatment would be unacceptable, per a two-stage Fleming multiple testing procedure.","groups":[{"description":"Intensity modulated radiation therapy (IMRT) for all patients and chemotherapy (cisplatin and fluorouracil) for patients with stage ≥ T2b and/or N+","id":"OG000","title":"IMRT +/- Chemotherapy"}],"paramType":"NUMBER","populationDescription":"First 57 eligible patients who started study treatment.","reportingStatus":"POSTED","timeFrame":"From start of treatment to end of treatment","title":"Protocol Compliance of Intensity-modulated Radiotherapy Treatment Delivered","type":"PRIMARY","unitOfMeasure":"participants"}